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Abstract
Background: Pseudoviruses (PsVs) that encapsidate a reporter plasmid DNA have been used as surrogates for
native human papillomavirus (HPV), whose continuous production is technically difficult. HPV PsVs have been
designed to form capsids made up of the major capsid protein L1 and the minor capsid proteins L2. HPV PsVs have
been produced in 293TT cells transfected with plasmid expressing L1 and L2 protein and plasmid containing the
reporter gene. Several studies have suggested that naturally occurring HPV virions contain cellular histones, and
histones have also been identified in mature HPV PsVs. However, the effect of the histones on the properties of the
PsVs has not been investigated. Using heparin chromatography, we separated mature HPV type 16 PsVs into three
fractions (I, II, and III) according to their heparin-binding affinities.
Results: The amounts of cellular histone and cellular nucleotides per PsV were found to increase in the order
fraction I, II and III. It appeared that PsVs in fraction I contains just small amount of cellular histone in Western blot
analysis. The proportions of the three fractions in PsV preparations were 83.4, 7.5, and 9.1 % for fraction I, II, and III
PsVs, respectively. In the electron microscope PsVs in fraction I appeared to have a more condensed structure than
those in fractions II and III. Under the electron microscope fraction II and III PsVs appeared to be covered by
substantial amounts of cellular histone while there was no visible histone covering PsVs of fraction I. Also the levels
of reporter gene expression in infections of fraction II and III PsVs to 293TT cells were significantly lower than those
in infections of fraction I PsV, and fraction II and III particles had significantly reduced immunogenicity.
Conclusions: Our findings suggest that the involvement of large amounts of cellular histones during PsV formation
interferes with the structural integrity of the PsVs and affects their immunogenicity. The fraction I particle therefore
has the most suitable characteristics for use as an HPV PsV.
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Background
Pseudoviruses (PsV) are synthetic viruses that can in-
clude genetic material such as DNA and RNA, and are
closely related to the structures and characteristics of its
native viruses, but lack characteristics shown in the
authentic viruses such as capability for replication [1].
PsV systems permit the continuous production of virus
particles mimicking naturally occurring particles, and
provide high-throughput systems for evaluating anti-
viral agents and vaccine candidates. Recently, various
types of PsV systems have been developed. The PsV sys-
tem for human immunodeficiency virus (HIV) uses the
TZM-bI cell line, a genetically modified HeLa cell line
expressing receptors for HIV and the firefly luciferase re-
porter gene under the control of the HIV long-terminal
repeat [2]. PsVs for Merkel cell polyoma virus (MCV)
have been generated by co-transfection with the VP1
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and VP2 genes of MCV strain 339 and a Green fluores-
cent protein (GFP) reporter plasmid of 293TT cells engi-
neered to stably express the cDNA of Simian virus 40
(SV40) T antigen [3]. Similar systems have been used for
the PsVs of polyoma virus JCPyV [4], enterovirus 71 [5]
and human papillomavirus (HPV) [6]. The HPV PsV sys-
tem has evolved along with the success of the commer-
cial vaccine against HPV. Currently the HPV PsV system
is the most straightforward and widely used system in
the HPV research field because the property of HPV
PsV is similar to that of native HPV virion.
HPV is a non-enveloped DNA virus that infects
cutaneous and mucosal epithelial tissues. Most cases of
cervical cancer are caused by infection with high-risk
HPV types [7, 8]. The HPV capsid is composed of 72
pentamers arranged on a T = 7 icosahedral lattice, each
containing an L1 capsomeres [9, 10]. The capsid also in-
cludes the minor capsid protein L2 [11]. It has been sug-
gested that the center of each capsomere is occluded
with an L2 protein, and the L2 protein is located within
the capsid [12, 13]. Some of the known roles of the L2
protein include facilitating capsid assembly, enhancing in-
fectivity, and encapsidation of the HPV genome [14, 15].
Continuous production of the native HPV virion is
difficult because its replication is strictly controlled by
the cell cycle of the host cell [16, 17]. For this reason,
synthetic HPV particles such as virus-like particles
(VLPs), PsVs and quasivirions (QVs) have been substituted
for native HPV virions in studies investigating aspects of
infection, transmission, immunogenicity, and viral struc-
ture [18]. VLPs are composed of the L1 protein alone or
L1 and L2 proteins [19–21], whereas the pseudovirus
capsid contains both L1 and L2 proteins, and encapsidates
reporter plasmid DNA [6]. QVs also contain L1 and
L2 proteins, and encapsulate full-length HPV genomes
[18, 22]. Capsid structure is thought to be stabilized
by intermolecular disulfide bonds between capsome-
res: an analysis of recombinant HPV16 VLPs sug-
gested that a critical intercapsomeric disulfide bridge
occurs between Cys428 and Cys175 [9, 10, 14]. In the
case of synthetic HPV virions such as PsVs, and un-
like in other viruses, a long period of maturation
(>24 h at 37 °C) is required because the formation of
disulfide bonds is slow [14].
The HPV genome is approximately 8 kb in length and
is replicated in the nucleus [18]. The genome of native
HPV virions is thought to have a chromatin-like struc-
ture that includes host histones [23], and cellular his-
tones are also thought to be present in the mature HPV
PsVs [13]. The presence of cellular histones has been
found to be associated with reduced infectivity of HPV
virions and of infectious PsVs. However, the properties
of the histone-carrying PsVs have not been investigated
in detail.
It is generally agreed that differences in the heparin
binding affinities of different viruses that attach to the
cell via heparin sulfate are responsible for differences
in their properties, such as virulence and pathogenesis
[24–29]. Since cellular histones bind strongly to hep-
arin [30], we hypothesized that the histone-containing
HPV PsVs would bind heparin more strongly than
those without histones. In the present work we identified
three types of HPV type 16 (HPV16) PsVs according to
their heparin-binding affinities, and compared their struc-
tures, infectivity and immunogenicity, in order to identify
the specific characteristics of histone-carrying PsVs.
Results
Separation of HPV16 PsVs by heparin chromatography
Mature HPV16 PsVs were produced in 293TT cells by
co-transfection of p16sheLL (expressing L1 and L2 pro-
teins) and pYSEAP (expressing SEAP) and purified by
size-exclusion chromatography (SEC, Fig. 1), and the
PsVs were subdivided into fractions I, II, and III accord-
ing to their heparin-binding affinities (Additional file 1:
Figure S1 and Additional file 2: Figure S2): the heparin
chromatography condition facilitates separation of PsVs
containing small amounts of cellular histone from those
with large amounts of histone. SEC demonstrated that
cellular histones are principally involved in the produc-
tion of HPV PsV (Fig. 1). It is known that correctly
folded HPV capsids and HPV PsVs can bind to heparin-
bound resin in 0.325 M NaCl at pH 7.2 [31, 32]. In the
present work 0.65 M NaCl at pH 7.2 was used for the
binding studies because under these conditions HPV
PsVs bind only when they contain substantial amounts
of histone (Additional file 1: Figure S1 and Additional
file 2: Figure S2). Thus the flow-through fraction under
these conditions was designated fraction I PsV. The PsVs
bound to the heparin were eluted successively with
buffer containing 0.8 M NaCl and buffer containing 1 M
NaCl, and the eluted PsVs were designated fraction II
and III PsVs, respectively (Additional file 1: Figure S1).
The detail sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) banding patterns of the
fractions from the heparin chromatography can be seen
in Additional file 2: Figure S2.
Comparison of histone and cellular DNA contents
To compare the histone H3 and H2B contents of the
three PsV types, identical amounts of PsVs (based on L1
protein content) were loaded (Fig. 2a). It was found that
the virus-associated contents of histone protein in-
creased in the order fractions I, II and III (Fig. 2a). PsVs
in fraction I appeared to contain small amounts of his-
tones H3 and H2B, which could be seen when the anti-
body reaction and film exposure times were extended
(Fig. 2b). It was confirmed that the amounts of cellular
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DNAs less than 1000 bp contained in the three PsVs
paralleled the amounts of histones (Fig. 2c). The L1 pro-
tein content of each fraction of PsV was determined by
sandwich enzyme-linked immunosorbent assay (ELISA)
(Fig. 2d), and the proportions of PsVs from fraction I, II,
and III inferred from this were 83.4, 7.5, and 9.1 %, re-
spectively (Fig. 2d). Therefore, PsV in fraction I, which
contains only a small amount of cellular histone, appears
to be the predominant type.
Comparison of the structural integrity of HPV16 PsVs
from fraction I, II and III
The PsVs were negatively stained with phosphotungstic
acid and observed by transmission electron microscopy
(TEM) (Fig. 3 and Additional file 3: Figure S3). Fraction
I PsVs appeared to be highly ordered and condensed and
to be slightly smaller than those from fractions II and III
(Fig. 3). Fraction II PsVs were also highly ordered but
their capsomers could be seen more clearly than those
of fraction I particles, indicating that they were more
loosely connected. Fraction III PsVs stained strongly and
appeared to consist of blackened particles (Fig. 3). Inter-
estingly, the fraction III PsVs had a fuzzy appearance
(Fig. 3 and Additional file 3: Figure S3), which we believe
was due to the large amounts of associated cellular his-
tones and DNA. When the PsVs were stained with
immunogold to detect human histone H3, the surfaces
of fractions II and III particles appeared to be covered
by this histone (Fig. 4). The TEM images indicated that
fraction I PsVs were smaller and had a more condensed
structure than fractions II and III PsVs.
Expression of reporter gene and reporter gene contents
of HPV16 PsVs from fraction I, II and III
The expression levels of reporter gene, secreted alkaline
phosphatase (SEAP), in the different PsV fractions were
compared (Fig. 5a). To use identical amounts of PsVs
from three heparin chromatography fractions, the L1
contents were determined by sandwich ELISAs and con-
firmed by Western blots prior to measure the SEAP
expressions. 293TT cells were plated in 96-well tissue
culture plates, and each type of PsV was serially diluted
Fig. 1 Purification of mature HPV16 PsVs by SEC. a SDS-PAGE and Western blots for human histone H3 of SEC fractions of a 293TT cell lysate
(control experiment). b SDS-PAGE and Western blots for detecting L1, L2 and human histone H3 of SEC fractions of a lysates of 293TT cells
transfected with p16sheLL and pYSEAP. c SDS-PAGE and Western blots for detecting L1 protein and human histone H3. Control refers to a mixture of
fractions 3 – 8 in panel a; PsV refers to a mixture of fractions 3 – 8 in panel b. M is a protein marker. PsVs eluted early (in fractions 3 to 8, red box in
panel b), whereas most cellular proteins eluted later (fractions 10 to 16), indicating that the PsVs were larger than most of the latter (b). Histone H3
co-eluted with L1 protein in fractions 4 to 6 (b) and there was no histone H3 in the corresponding fractions of the 293TT cell control (a). Fractions 3–8
from the 293TT cell control were combined, as were fractions 3–8 from the 293TT cells producing HPV16 PsVs (red boxes in a and b); they were then
analyzed by SDS-PAGE and Western blotting (c)
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from 25 ng/mL to 0.39 ng/mL and incubated for 72 h at
37 °C (Fig. 5a). Moreover, the reporter gene contents of
PsVs from three fractions were determined by quantita-
tive real-time polymerase chain reaction (PCR) (Fig. 5b).
The SEAP expression levels were significantly lower in
fraction II and III PsVs than in fraction I (Fig. 5a)
whereas the amount of the pYSEAP reporter plasmid as-
sociated with fraction II particles appeared to be similar
to that associated with fraction I particles (Fig. 5b). The
amount of the pYSEAP reporter plasmid associated with
fraction III particles was substantially lower (Fig. 5b).
Agarose gel analysis (Additional file 4: Figure S4) sup-
ported the result of the quantitative real-time PCR in
Fig. 5b. These results indicate that substantial amounts
of cellular histones are detrimental for formation of PsV
with high expression level of SEAP.
The immunogenicity of HPV16 PsVs from fraction I, II
and III
Mice were immunized three times with HPV16 PsVs,
and neutralizing antibody titers were measured (Fig. 6).
Fraction II and III PsVs elicited lower levels of neutraliz-
ing antibody (Fig. 6) than fraction I PsV. In addition, the
mice immunized with PsVs from fraction III gave only
weak lymphoproliferative responses upon stimulation
with HPV16 L1 VLPs (Additional file 5: Figure S5).
Discussion
Our results indicated that condensed structure, a sub-
stantial amount of a plasmid containing the reporter
gene and a low content of cellular histones are import-
ant for the formation of infectious and immunogenic
HPV16 PsVs. Of the HPV16 PsVs, 83 % appeared to be
fraction I PsVs, which fulfil the requirements for highly
infectious and immunogenic PsVs (Fig. 2d), whereas
about 17 % of the PsVs (particles from fraction II and
III) were found to have lower infectivity and immuno-
genicity (Fig. 2d). Therefore, it appears that most HPV16
PsV undergo assembly and maturation with high fidelity.
PsVs are known to undergo assembly within the cell,
and the resulting particles are in an immature state with
their capsomers only loosely connected to each other
immediately after cell lysis [14]. These immature PsVs
can be condensed and stabilized by a maturation process
that requires incubation at 37 °C overnight [14]. It has
been suggested that there are substantial losses of virus
Fig. 2 Analysis of histones, cellular DNA contents and proportions of HPV16 PsVs from fraction I, II and III. a shows SDS-PAGE and Western blots
comparing the L1, histone H3 and histone H2B contents of the three types of PsVs. b shows SDS-PAGE and Western blots for detecting L1,
histone H3 and histone H2B in type I PsVs. b is a repeat of panel A but with extended film exposure for Western blots. c is a result of agarose gel
showing cellular DNA contents of PsVs from fraction I, II and III. d is result showing the proportions of PsVs from fraction I, II and III. To calculate
the proportion of each type, their L1 content was determined by sandwich ELISA. Data represent the mean ± SD of four independent experiments
Kim et al. BMC Biotechnology  (2016) 16:63 Page 4 of 10
titer and of encapsidated reporter gene plasmids during
the purification of immature PsV [14]. Recently, Cardone
and colleagues analyzed the structures of HPV16 PsVs
by time-lapse cryo-electron microscopy [33]. They re-
ported that the diameter of the immature PsVs shrank
by ∼ 5 % in the maturation process during which the
interaction surfaces between adjacent capsomers were
consolidated. As shown in Fig. 3 PsVs from fraction I are
slightly smaller and more condensed than those from
fraction II or III. In addition the capsomers of fraction II
particles were less tightly connected. Infections with par-
ticles in fraction II and III led to the much lower expres-
sion of SEAP than infections with particles in fraction I
(Fig. 5a). Therefore, the integrities of fraction II and III
particles are similar to those of immature PsVs while the
integrity of fraction I particles correspond to that of ma-
ture PsVs.
SEAP expression was significantly reduced in PsVs
from fraction II (Fig. 5a) as was the elicitation of neutral-
izing antibodies (Fig. 6) although they harbor substantial
levels of reporter gene plasmids (Fig. 5b) and have rela-
tively satisfactory architectural structures (Fig. 3). The
position of the L2 protein is known to be important for
encapsidation of the reporter gene plasmid [13, 14].
However, we found that the three PsV types did not
differ in terms of their L2 protein content (Additional
file 6: Figure S6). In addition, ELISAs using monoclonal
antibodies H16.V5 and H16.E70, which have been widely
used for detecting neutralizing epitopes of the HPV16
capsid, indicated that the level of neutralizing epitopes
on the surface of fraction II particles was similar to the
level on the surface of fraction I particles (Additional file
7, Figure S7). Therefore, it seems that the structural ro-
bustness of fraction II PsVs is not enough for efficient
delivery of the reporter gene into target cells, and its
neutralizing epitopes are not recognized correctly by
cells of the immune system. PsVs in fraction II were
found to be covered by substantial amounts of cellular
histones and cellular nucleotides (Fig. 4) and it seems
likely that these interfere with binding of the PsVs to cell
receptors and their correct recognition by immune cells.
Previous reports have indicated that viral DNAs con-
taining histone, and naked DNAs without histone, coex-
ist in native HPV preparations, and it was suggested that
the DNAs of bovine papillomavirus (BPV) and HPV
have a chromatin-like structure composed of nucleo-
somes about 8.0 nm in diameter, interconnected by
naked DNA filaments [23]. Histone-free HPV DNA has
been found in native HPV virions [23], and there are no
histones in purified BPV [34]. Therefore, the suggestion
Fig. 3 TEM analysis of HPV16 PsVs of fractions I, II and III. The presented images were representatives from triple observations. Magnification is
234,000× (bar 100 nm)
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has been made that the complex of HPV DNA with
nucleoproteins is a natural intermediate during virion
assembly.
The histone-containing fractions in our study were
derived from HPV16 PsVs rather than native HPV vi-
rions. Our results indicated that the presence of cellular
histones was detrimental to the formation of infectious
PsV. However, whether the binding of histone to the sur-
face of HPV16 PsVs shown in Fig. 4 is inherent to the
HPV virion remains to be clarified. The suggested model
of the assembly of HPV capsid is that the C-terminal
proximal H4 helix of each L1 molecule in a capsomere
invades a neighboring L1 molecule in an adjacent cap-
somere and forms an intermolecular disulfide bond [10].
Fig. 5 Quantification of SEAP and pYSEAP. a Relative SEAP expressions of PsV particles. Each type of PsV was serially diluted from 25 to 0.39 ng/mL
(based on the L1 protein concentrations), and SEAP expression levels were determined as described in Methods. b Relative pYSEAP amounts of PsV
particles. The values for fraction I PsVs in panel b were set at 100 %. a shows the mean ± SD of duplicate samples, and b presents the mean ± SD of
four independent experiments. **, p < 0.01
Fig. 4 TEM analysis of HPV16 PsVs from fraction I, II and III stained with immunogold. Human histone H3 protein was detected with rabbit anti-
human histone H3, together with 5 nm gold-labeled anti-rabbit IgG as described in Methods. Magnification is 234,000× (bar 100 nm)
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L1 protein has a DNA binding domain at its C-terminus
[35]. Therefore, there are two kinds of explanation for
the effects of cellular histone. First, since immature
HPV16 PsVs have greater space between neighboring
capsomers (Fig. 3, see particles from fraction II) they
may expose more of their DNA binding domains and so
allow more binding of cellular DNA plus histones. Alter-
natively, the presence of cellular histones and cellular
DNAs during assembly of the capsid may hinder con-
densation of the capsids.
Conclusions
Our results suggest that a low content of cellular histone
and cellular DNA of HPV16 PsV and a condensed struc-
ture are important for the formation of high quality
HPV16 PsVs. We believe that the content of cellular his-
tone is a critical parameter for assessing the quality and
stage of maturation of HPV16 PsV. Also, the heparin
chromatography technique described here appears to be
a useful tool for separating PsV particles of high quality
from the total pool of mature PsVs.
Methods
Production and purification of mature PsVs
HPV16 PsVs were produced as described by Buck and
colleagues (standard protocol) [14, 36]. 293TT cells were
transfected with p16sheLL (expressing L1 and L2 pro-
teins) and pYSEAP (expressing SEAP) using Lipofecta-
mine 2000 (Invitrogen, USA). The transfected cells were
cultured for 72 h then harvested and lysed. The plasmids
were kindly provided by Dr. J. T. Schiller (NIH, Bethesda,
USA). To prepare a mature PsV stock, the lysate was
treated with 0.1 % Benzonase (Sigma, USA) and 0.1 %
Plasmid Safe (Epicentre, USA) DNase, and incubated for
24 h at 37 °C. The NaCl concentration of the lysate was
adjusted to 0.8 M and clarified by centrifugation at
12,000 × g for 10 min at 4 °C. The PsVs in the clarified lys-
ate were purified by SEC as follows: the clarified lysate
(0.5 mL) was loaded onto a column (Tricon 10/300, 1 ×
32 cm, GE Healthcare, USA) packed with Superose-6
resin (GE Healthcare, USA). The column was equilibrated
with working buffer [phosphate buffered saline (PBS) +
0.52 M NaCl + 0.01 % Tween 80 pH 7.2, final NaCl con-
centration 0.65 M] prior to loading the sample, and the
SEC was performed at a flow rate of 0.3 ml/min. Twenty
fractions (0.9 mL each) were collected and analyzed by
SDS-PAGE and Western blotting.
Separation of PsVs by heparin chromatography
To separate fraction I, II and III PsVs, we modified our
previous protocol for heparin chromatography [31]. A
9 cm poly-prep column (Bio-Rad, USA) was packed with
0.1 ml heparin fast-flow resin (HiPrep™ Heparin FF, GE
Healthcare, USA) and equilibrated with binding buffer
[PBS + 0.52 M NaCl + 0.01 % Tween 80 pH 7.2, final
NaCl concentration 0.65 M]. The PsV-containing frac-
tions from the SEC were pooled and loaded onto the
heparin resin, and the capsids eluted without being
bound (flow-through and wash), eluted with 0.8 M NaCl,
and eluted with 1 M NaCl were considered to be frac-
tion I, II, and III PsVs, respectively. The flow-through
and eluted PsV fractions were monitored by SDS-PAGE
and Western blots.
SDS-PAGE and Western blotting
SDS-PAGE was performed according to the Laemmli’s
protocol using a Mini-PROTEAN® Tetra Cell (Bio-Rad,
USA). The protein bands on SDS-PAGE gels were visu-
alized by silver staining. To detect the L1 protein by
Western blotting, rabbit anti-HPV16 L1 serum and
HRP-conjugated goat anti-rabbit IgG polyclonal anti-
body (Pierce, USA) were used [37]. Histone H3 was de-
tected using rabbit anti-human histone H3 (sc-10809,
Santa Cruz Biotechnology, USA) or rabbit anti-human
histone H3 (ab1791, Abcam, USA), while histone H2B
was detected with rabbit anti-human H2B (ab61250,
Abcam, USA). HRP-conjugated anti-rabbit immuno-
globulin G (IgG) (Bethyl, USA) was used as secondary
antibody for detecting histones.
Analysis of cellular DNA
The L1 protein content of each PsV type was determined
by Western blotting and SDS-PAGE. 1 μg of L1 protein
of each type was used for analyzing the content of cellu-
lar DNA. The DNA was extracted by precipitation with
Fig. 6 Antibody responses following three immunizations with
50 ng of PsVs per dose. Mice were immunized with PsVs (fraction I, II
and III) without adjuvant. Neutralizing antibody titers against HPV16
PsVs in mouse sera were determined as described in Methods.
Horizontal bars correspond to median values. PBS, n = 7; type I, n = 7;
type II, n = 7; type III, n = 7
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phenol-chloroform-isoamyl alcohol mixture (Sigma,
USA), washed with 70 % ethanol and analyzed on 0.9 %
agarose gels with ethidium bromide staining.
Measurements of L1 protein amounts in HPV16 PsVs from
fraction I, II, and III
To assess yields of PsVs from fraction I, II and III, their
L1 protein content was determined by sandwich ELISA
as previously described [32]. Purified HPV16 L1 VLPs
were used as a standard. The amounts of L1 protein
were confirmed by SDS-PAGE and Western blotting.
TEM analysis
Purified PsVs (5 μg/mL) from fraction I, II and III were
absorbed onto carbon-coated grids and negatively
stained with 2 % phosphotungstic acid. To detect his-
tone H3 on the surface of the PsVs, the latter were
absorbed onto a carbon-coated grid, and incubated with
rabbit anti-histone H3 (ab1791, Abcam, USA) followed
by 5 nm gold-labeled goat anti-rabbit IgG polyclonal
antibody (ab27235, Abcam, USA). Thereafter the PsVs
were fixed with 1 % glutaraldehyde (Sigma, USA) and
stained with 2 % uranyl acetate. Electron microscopy
was performed on a TEM200CX at a final magnification
of 234,000× [31].
Determination of the level of SEAP expression per PsV
particle
To determine SEAP expression levels of PsVs from
fraction I, II and III, the L1 protein content of each type
was determined as described above and confirmed by
Western blotting. 293TT cells were plated in 96-well tis-
sue culture plates at a density of 3 × 104 cells/well for
4 h prior to PsV infection, and each type of PsV was
serially diluted from 25 ng/mL to 0.39 ng/mL (based on
the L1 protein concentrations) and incubated for 72 h at
37 °C. SEAP content was measured at 405 nm [31].
Quantitative real-time PCR for pYSEAP in PsVs
To measure pYSEAP content per particle, equal
amounts of PsVs from fraction I, II and III were used
(200 ng based on L1 content). pYSEAP was extracted
from the PsVs using a PCR extraction kit (Real Biotech
Corporation, Taiwan). Prior to the extraction, the PsV
stocks were treated with proteinase K (Qiagen, Germany)
at 56 °C for 20 min to release encapsulated pYSEAP, and
spiked with pcDNA3.1+ (Invitrogen, USA) as a reference.
The primers for detecting pYSEAP were 5′-TTT AAC
CAG TGC AAC ACG ACA CGC-3′ (sense) and 5′-TCC
CAC TGA CTT CCC TGC TTT CTT-3′ (antisense), and
those for detecting pcDNA3.1+ were 5′-ATA CGG GAT
AAT ACC GCG CCA CAT-3′ (sense) and 5′-TGC ACG
AGT GGG TTA CAT CGA ACT-3′ (antisense). Real-
time PCR was performed using a QuantiTect SYBR Green
PCR Kit (Qiagen, Germany) on an iCycler real-time PCR
machine (Bio-Rad, USA). The crossing threshold (Ct)
value of pYSEAP was normalized to that of pcDNA3.1+.
Mouse immunization
Six-week-old female BALB/c mice (Orient Bio, South
Korea) were assigned to four groups of seven mice each:
PBS and PsVs from fraction I, II and III. The mice were
subcutaneously immunized three times at two-week in-
tervals with PsVs without adjuvant. The control group
received 100 μL of PBS per dose, and the others received
50 ng of type I, II, or III PsVs per dose. Mouse sera were
collected 10 days after the third immunization.
Titrations of anti-HPV16 neutralizing antibodies from
mice immunized with HPV16 PsVs
The neutralizing assays using HPV16 PsVs were per-
formed as previously described [6, 38] The neutralization
titer of a mouse serum was defined as the reciprocal of the
highest dilution that caused a reduction of at least 50 % in
SEAP activity [39].
Statistical analysis
The statistical significance of differences between ex-
perimental groups was determined by two-tailed Student’s
t-tests.
Additional files
Additional file 1: Figure S1. Schematic diagram of heparin
chromatography to separate HPV16 PsVs into fraction I, II and III.
(DOCX 75 kb)
Additional file 2: Figure S2. SDS-PAGE analysis of heparin chromatography
fractions containing HPV16 PsVs. Mature HPV16 PsVs purified by SEC were
further separated by heparin chromatography. The binding buffer for
heparin chromatography contains 0.65 M NaCl. LS, FT and W refer to
loading sample, flow-through, and wash, respectively. M indicates a protein
marker. The PsVs in the flow-through and wash fractions were designated
fraction I. PsVs in fraction II and III were eluted from the heparin resin by
successive additions of 0.8 and 1 M NaCl. (DOCX 197 kb)
Additional file 3: Figure S3. TEM analysis of HPV16 PsVs from fraction I,
II and III. Magnification x 234,000 (bars are 50 or 100 nm). (DOCX 1656 kb)
Additional file 4: Figure S4. PCRs for reporter genes in HPV16 PsVs
from fractions I, II and III. A shows the pYSEAP contents of PsVs from
fraction I, II and III. B confirms the specificity of the PCR for the relevant
region of the pYSEAP construct. Buffer only and pcDNA3.1 are negative
controls. To measure pYSEAP content per particle, in panel A, identical
amounts of PsVs from fraction I, II, and III were used (20 ng based on L1
content). 25, 30 or 38 cycles of PCR were carried out. Thirty cycles of
PCR were performed for panel B. The same primer set used in the
quantitative real time PCR for amplifying the 80 bp region of pYSEAP was
used (see the quantitative real time PCR section in Methods). Amplicons
were analyzed on a 1.5 % agarose gel. (DOCX 406 kb)
Additional file 5: Figure S5. Lymphoproliferative responses following
four immunizations with HPV16 PsVs from fraction I, II, or III. The mice
were immunized four times with 50 ng of PsVs per dose at 2-week
intervals. Mouse splenocytes were obtained 5 days after the fourth
immunization. Mouse splenocytes were labeled with carboxyfluorescein
succinimidyl ester (CFSE), stimulated with purified HPV16 L1 VLPs, and
cultured for 4 days. The splenocytes were stained with allophycocyanin
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(APC)-conjugated anti-CD4 antibody (eBioscience, USA) and examined
with a FACSCalibur flow cytometer (BD Bioscience, USA). To count CD4+
cells, the cells were gated according to forward and side scatter, and the
upper-left segment of each graph was counted on FITC and APC scatter
plots. Panel A shows the flow cytometry results for three individual mice.
The value in panel B represents the mean ± SEM (n = 3). (DOCX 171 kb)
Additional file 6: Figure S6. L2 protein contents of HPV16 PsVs from
fraction I, II and III. To detect the L1 and L2 proteins, 100 or 200 ng of
PsVs was loaded per well (based on the L1 amount). The L2 protein was
detected by Western blotting using the anti-RG1-4MAP mouse serum
(1:500 dilution) with HRP conjugated goat anti-mouse IgG antibody
(Bethyl Laboratories). The proteins on SDS-PAGE gels were visualized by
silver staining. The quantities of the L2 protein per PsV particle were
similar for all three types of PsV. (DOCX 153 kb)
Additional file 7: Figure S7. Reacitivities of HPV16 PsVs from fraction I,
II and III with H16.V5 or H16.E70 MAbs. The reactivities of fraction I PsVs
were set at 100 %. The values are the mean ± SD of quadriplicate assays.
(DOCX 43 kb)
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